Generation Bio Stock (NASDAQ:GBIO)
Previous Close
$1.68
52W Range
$1.10 - $4.65
50D Avg
$2.36
200D Avg
$2.77
Market Cap
$102.86M
Avg Vol (3M)
$117.73K
Beta
2.82
Div Yield
-
GBIO Company Profile
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
GBIO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| NUVB | Nuvation Bio Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| KRON | Kronos Bio, Inc. |
| PASG | Passage Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| FIXX | Q32 Bio Inc. |
| STTK | Shattuck Labs, Inc. |